the aid library

LIST OPTIONS

Filter

6403

Sort by:

Direction:

Download (209)

View PDF (145)

WHO standard: universal access to rapid tuberculosis diagnostics

World Health Organisation (WHO) (2023) C_WHO

The WHO standard: Universal access to rapid tuberculosis diagnostics sets benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs), increase bacteriologically confirmed tuberculosis and drug resistance detection, and reduce the time to diagnosis. WHO-recommended rapid diagn... more

Download (197)

View PDF (542)

National Guidelines for Diabetic Eye Care

Ministry of Health Malawi (2021) CC

Diabetes mellitus (DM) is a global epidemic with significant morbidity. Diabetic retinopathy (DR) is the specific microvascular complication of DM and affects 1 in 3 persons with DM. DR remains a leading cause of vision loss in working adult populations. Patients with severe levels of DR are report... more

Download (113)

View PDF (138)

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr... more

Download (112)

View PDF (125)

Guidelines on Management of COVID-19 in Kenya
recommended

Ministry of Health, Kenya (2021) CC

It has been over a year since Kenya identified the first case of COVID-19 in the country. The Government formed the National COVID-19 task force, which supported the country's response through multi-sectoral technical working groups on testing, case management, risk communication and community engag... more

Download (312)

View PDF (378)

Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
recommended

World Health Organization WHO (2020) C1

To save the lives of mothers and their babies, mitigate complications, and limit the spread of disease, it is critical that recommendations are made on the prevention, treatment, and surveillance of women who are exposed to EVD, acquire EVD during pregnancy or breastfeeding, or survive EVD with ongo... more

Download (122)

View PDF (193)

National Guidelines for the Management of Viral Hepatitis

Spearman, CWN; MW Sonderup, Y Pillay et al. National Department of Health South Africa (2020) CC

Viral hepatitis is defined as inflammation of the liver cells due to viral infection. The burden of liver disease in South Africa is mostly underestimated as viral hepatitis, in particular chronic infection, is a silent and neglected cause of morbidity and mortality. However, the burden of disease i... more

Download (406)

View PDF (483)

Developing drinking-water quality regulations and standards: general guidance with a special focus on countries with limited resources

World Health Organization (WHO) (2018) CC

Drinking-water quality regulations and standards developed or revised in accordance with this guidance will reflect the best practices identified in the WHO Guidelines for Drinking-water Quality to most effectively protect public health. Moreover, the regulations and standards will consider local ne... more

Download (267)

View PDF (335)

National Guidelines for Prevention and Management of HIV, STIs & Other Blood Borne Infections

Ministry of Health, Rwanda & Rwanda Biomedical Centre (2013) C2

These are integrated National Guidelines 2013 for Prevention and Management of HIV, STIs & Other Blood Borne Infections in accordance with the last guidelines of the World Health Organization (WHO) published in June 2013 and adapted to the Rwandan national context. It thus responds to the need by th... more

Download (1244)

View PDF (2099)

Infection Control outside the VHF Treatment Facility

MSF (2008)

This section deals with implementing and improving infection control practices in hospitals, health centres and other health services in the outbreak area. It explains the need for, and implementation of, effective triage procedures, and basic requirements for infection control and supporting activi... more

Download (407)

View PDF (931)

WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants

World Health Organization (WHO) (2003) C_WHO

The main objectives of these guidelines are to:
1. contribute to the quality assurance of medicinal plant materials used as the source for herbal medicines to improve the quality, safety and efficacy of finished herbal products; 2. guide the formulation of national and/or regional GACP guideli... more

Download (219)

View PDF (215)

Guidelines for Risk Analysis of Foodborne Antimicrobial Resistance

Food and Agriculture Organization of the United Nations FAO (2021) CC

Antimicrobial resistance (AMR) is a major global public health concern and a food safety issue. When pathogens become resistant to antimicrobial agents they can pose a greater human health risk as a result of potential treatment failure, loss of treatment options and increased likelihood and severi... more

Download (765)

View PDF (1428)

Guidelines for Implementing Collaborative TB and HIV Programme Activities

Stop TB Partnership. Working Group on TBHIV. Scientific Panel WHO (2003) C_WHO

The main aim of these guidelines is to enable the central units of national TB and HIV/AIDS programmes to support districts to plan, coordinate and implement collaborative TB/HIV activities. These guidelines reinforce current medical understanding, that highly active antiretroviral treatment (HAART)... more

Download (107)

View PDF (166)

Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis
recommended

World Health Organization WHO (2022) C_WHO

These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB. This Ra... more

Download (161)

View PDF (228)

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended

World Health Organization WHO (2020) C_WHO

Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people ... more

Download (1469)

View PDF (1480)

Global update on HIV treatment 2013: Results, impact and opportunities

World Health Organization; UNICEF; UNAIDS (2013)

Chapter 1 provides new data on the latest developments in the global treatment effort, highlighting positive trends as well as aspects that require improvement. Chapter 2 summarizes the impact of the scale-up in reducing AIDS-related mortality and new HIV infections. Chapter 3 examines the sequence ... more

Download (52)

View PDF (35)

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

Download (151)

View PDF (303)

Guidelines for drinking-water quality: Small water supplies

World Health Organization WHO (2024) C_WHO

Small drinking-water supplies commonly experience operational, managerial, technical and resourcing challenges that impact their ability to deliver safe and reliable services. The needs and opportunities associated with these supplies therefore warrant explicit consideration in policies and regulati... more

Download (261)

View PDF (356)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (119)

View PDF (139)

Guidelines for Care of Critically Ill Adult Patients with COVID-19 in the Americas. Summary, version 3

Pan American Health Organisation PAHO (2021) C_WHO

This publication provides recommendations for the management of critically ill adult patients with COVID-19 being treated in intensive care units (ICUs) in the Americas. These clinical practice guidelines provide evidence-informed recommendations for identifying markers and mortality risk factors in... more

Download (245)

View PDF (273)

Guideline for Preventive Chemotherapy for the Control of Taenia solium Taeniasis

Pan American Health Organisation PAHO (2021) C_WHO

The larval stage of the parasite Taenia solium can encyst in the central nervous system causing neurocysticercosis, which is the main cause of acquired epilepsy in the countries in which the parasite is endemic. Endemic areas are those with the presence (or likely presence) of the full life cycle of... more

Guidelines on Management of COVID-19 in Kenya recommended

Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease recommended

Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV recommended

Guidelines on Management of COVID-19 in Kenya
recommended

Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
recommended

Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis
recommended

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
recommended